Epigenetic drugs can increase tumour malignancyResearchers at IRB Barcelona report that tumours may become more aggressive following treatment with drugs that inhibit epigenetic factors. more ➔
Forbion leads €40m financing in Inflazome LtdInflammosome inhibitor specialist Inflazome Ltd has raised €40m in a Series B financing led by Forbion with co-investors Longitude Capital, Novartis Venture Fund and Fountain Healthcare Partners. more ➔
EC advisors call for update of GM legislationThe EU Commission’s Chief Scientific Advisors urge the Commission to revise the EU’s GMO Directive in order to harness gene editing. more ➔
Boehringer and Epizyme enter US$300m dealBoehringer Ingelheim and Epizyme, Inc. will collaborate in the field of small molecule cancer drugs that target unaddressed epigenetic targets within the helicase and histone acetyltransferase famil … more ➔
Breakthrough in restless legs syndromeResearchers at University of Göttingen, Germany, have identified nerve excitability of motor nerve cells trigger restless legs syndrome. more ➔
SOBI and AstraZeneca in US$2bn+ deal on RSV antibodiesAstraZeneca plc has sold US rights to its off-patent blockbuster drug Synagis (palivizumab) and a 50% share on future earnings of its Phase II RSV-prophylactic follow-on antibody MEDI8897 to Swedish … more ➔
Amal bags €21.2m financingSwiss Amal Therapeutics S.A. (Geneva) has raised €21.2m in a series B follow-up financing. more ➔
Antibiotic resistance spreading across EuropeAntimicrobial resistance (AMR) has increased by 32% since 2007 in Europe, according to a brand new report. more ➔
Liquid biopsy: size mattersA new method developed by Swiss, Danish and British researchers allows to detect hard-to-trace tumour-derived DNA in the blood (or ctDNA). more ➔
Themis postpones IPOOne week after Austrian vaccine and cancer immunotherapy specialist Bioscience announced the terms of its initial public offering (IPO) and listing on Euronext Amsterdam, the company has postponed its … more ➔
